Oxford BioDynamics reports good results from EpiSwitch

Biotechnology company Oxford BioDynamics announced on Thursday that, using its proprietary technology platform EpiSwitch, it has been successful in diagnosing breast cancer in a Caucasian cohort of patients provided by the Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology (MCMCC) in Poland.